News
- Author:
- Myles Starr
Publish date: April 18, 2024
Experts debated about whether and when patients with relapsed/refractory follicular lymphoma should receive CAR T-cell therapy.
News
- Author:
- Myles Starr
Publish date: April 12, 2024
Both CAR T-cell therapy and bispecific antibodies are helping patients with patients with R/R ALL live longer, but which treatment is better?
News
- Author:
- Myles Starr
Publish date: January 17, 2024
The program, started to help Massachusetts dermatologists innovate, has mushroomed into a pipeline for innovation across specialties.
News
- Author:
- Myles Starr
Publish date: December 5, 2023
Many patients and their caregivers are enthusiastic about the idea of treatment that does not involve pharmaceuticals and that these options, while...
News
- Author:
- Myles Starr
Publish date: November 3, 2023
Relapsed and refractory DLBCL patients treated with CAR T-cell therapy achieved better outcomes than with autologous stem cell transplants.
News
- Author:
- Myles Starr
Publish date: October 27, 2023
Experts seek global collaboration to develop novel therapies for peripheral T-cell lymphomas, a rare form of non-Hodgkin lymphoma with many subtype...
News
- Author:
- Myles Starr
Publish date: October 25, 2023
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple myel...
News
- Author:
- Myles Starr
Publish date: September 20, 2023
Efforts are underway to alleviate an acute shortage of U.S. physicians who’ve been trained to treat hemostasis, thrombosis and other blood disorder...
News
- Author:
- Myles Starr
Publish date: July 3, 2023
Results of the clinical trial of a CLL drug triplet therapy, presented at ASCO 2023, showed that more data are needed to determine its long-term po...
News
- Author:
- Myles Starr
Publish date: June 5, 2023
A just-published retrospective study shows nearly 30 years of steady progress in lengthening the lives of U.S. adults with CLL and other leukemias....
News
- Author:
- Myles Starr
Publish date: May 17, 2023
After decades of slow progress, new drugs and therapies are paving the way to more effective treatment of DLBCL.
News
- Author:
- Myles Starr
Publish date: May 3, 2023
Overall survival following multidrug regimens and transplant are on par, raising questions about the best frontline therapy for multiple myeloma.
News
- Author:
- Myles Starr
Publish date: April 24, 2023
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
News
- Author:
- Myles Starr
Publish date: April 17, 2023
Venetoclax, with a second-generation generation Bruton’s tyrosine kinase inhibitor, can lead patients with relapsed CLL back to remission.
News
- Author:
- Myles Starr
Publish date: April 5, 2023
New study showed how leukemia specialists can harness measurable residual disease to gauge the efficacy of novel treatment options.
